Why UniQure Stock Is Trading Down Today
Portfolio Pulse from Ryan Gustafson
UniQure N.V. (NASDAQ:QURE) shares are trading lower after the company announced interim data from the Phase I/II trial of AMT-130 in Huntington's Disease. The data showed preliminary evidence of clinical and functional benefits, but the stock price fell 38.1% to $12.03. HC Wainwright & Co. analyst Patrick Trucchio reiterated a Buy rating and maintained a $90 price target.

June 21, 2023 | 7:09 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
UniQure's stock price fell after announcing interim data from the Phase I/II trial of AMT-130 in Huntington's Disease, despite positive preliminary results.
UniQure's stock price fell 38.1% after the announcement of interim data from the Phase I/II trial of AMT-130 in Huntington's Disease. Although the data showed preliminary evidence of clinical and functional benefits, the market reacted negatively to the news. However, HC Wainwright & Co. analyst Patrick Trucchio reiterated a Buy rating and maintained a $90 price target, indicating potential upside in the future.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100